When Zheng Xiaoyu took the helm of the Chinese State Food and Drug Administration (SFDA) nine years ago, hopes were high for effective regulatory oversight of China's drug industry. Now those hopes have been dashed with tragic personal consequences for Zheng and allegations of widespread corruption by Chinese officials.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Related links
Related links
Related links in Nature Research
Web links
China State Food and Drug Administration
Rights and permissions
About this article
Cite this article
Jia, H. China syndrome—a regulatory framework in meltdown?. Nat Biotechnol 25, 835–837 (2007). https://doi.org/10.1038/nbt0807-835
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0807-835
This article is cited by
-
Backlog cripples China's drug regulator
Nature Biotechnology (2015)
-
Chinese health biotech and the billion-patient market
Nature Biotechnology (2008)
-
Chinese manufacturers vie for piece of outsourcing pie
Nature Biotechnology (2007)
